Semaglutide is linked to a reduced risk for Alzheimer’s disease-related dementia in patients with diabetes vs other antidiabetic drugs, a new study suggests.

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's ...

Over 100 cases of acute pancreatitis have been reported to UK health regulators this year, many tied to the newest GLP-1 drug ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

The medicines regulator is investigating after hundreds of people have reported problems with their pancreas linked to taking ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications ...